Nadofaragene Firadenovec Shows Durable Responses in NMIBC
Stephen Boorjian, MD, discusses the efficacy results of the phase II study intravesical nadofaragene firadenovec in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer, which he presented at the 2020 Genitourinary Cancer Symposium.
Stephen Boorjian, MD, professor of Urology, Mayo Clinic, discusses the efficacy results of the phase III study intravesical nadofaragene firadenovec (Instilladrin) in patients with high-grade, Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer (NMIBC), which he presented at the 2020 Genitourinary Cancer Symposium.
The primary finding from the study was that 53% of patients with carcinoma in situ achieved a complete response following treatment with nadofaragene firadenovec, meeting the primary end point of the study.
Another key finding of the study is that the responses observed in these patients were durable, Boorjian reports.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
